IPG-GALANTAMINE ER CAPSULE (EXTENDED RELEASE)

Ország: Kanada

Nyelv: angol

Forrás: Health Canada

Aktív összetevők:

GALANTAMINE (GALANTAMINE HYDROBROMIDE)

Beszerezhető a:

MARCAN PHARMACEUTICALS INC

ATC-kód:

N06DA04

INN (nemzetközi neve):

GALANTAMINE

Adagolás:

24MG

Gyógyszerészeti forma:

CAPSULE (EXTENDED RELEASE)

Összetétel:

GALANTAMINE (GALANTAMINE HYDROBROMIDE) 24MG

Az alkalmazás módja:

ORAL

db csomag:

10

Recept típusa:

Prescription

Terápiás terület:

PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS

Termék összefoglaló:

Active ingredient group (AIG) number: 0144660005; AHFS:

Engedélyezési státusz:

APPROVED

Engedély dátuma:

2016-09-07

Termékjellemzők

1
PRODUCT MONOGRAPH
PR
IPG-GALANTAMINE ER
galantamine hydrobromide extended release capsules
8 mg, 16 mg, 24 mg galantamine base
Cholinesterase Inhibitor
Marcan Pharmaceuticals Inc.
Date of Revision:
77 Auriga Drive, Unit# 4
November 27, 2017
Ottawa, ON, CANADA
K2E 7Z7
Control No.: 210932
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...............................................................................
3
SUMMARY PRODUCT INFORMATION
.................................................................................................
3
INDICATIONS AND CLINICAL USE
......................................................................................................
3
CONTRAINDICATIONS
............................................................................................................................
3
WARNINGS AND PRECAUTIONS
..........................................................................................................
3
ADVERSE REACTIONS
............................................................................................................................
7
DRUG INTERACTIONS
...........................................................................................................................
12
DOSAGE AND ADMINISTRATION
......................................................................................................
14
OVERDOSAGE
.........................................................................................................................................
15
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................................
16
STORAGE AND STABILITY
..................................................................................................................
20
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................................
20
PART II: SCIENTIFIC INFORMATION
.............................................................................................